Biotech firm receives patent for psilocybin-derived mental health therapeutics

A Boston-area biotechnology firm announced it has received a patent titled “Carboxylated Psilocybin Derivatives and Methods of Using” for its EVM301 series of molecules to treat a range of mental health disorders.

According to a release from Enveric Biosciences, the patent, which was issued Sept. 12, grants the company intellectual property rights with claims to novel compositions and pharmaceutical drug formulations for a family of carboxylated derivatives of tryptamine-based drug candidates, which are in development to treat such conditions as anxiety, depression and substance use disorders.

Enveric’s EVM301 series features tryptamine derivatives designed to engage the serotonin 5HT2a receptor and other neurotransmitter receptors for improved neuroplasticity and therapeutic benefit without inducing hallucinatory effects, per the release.

“We believe this could greatly enhance the commercial opportunity of EVM301 series-based therapies, benefiting patients and healthcare systems broadly by reducing the need for costly and time-intensive requirements for supervision throughout the treatment,” Enveric CEO Joseph Tucker, PhD, said in the release. “For these reasons, Enveric is seeking to build a robust intellectual property portfolio for our EVM301 series with this U.S. patent providing a critical IP cornerstone.”